Dapagliflozin for the treatment of type 2 diabetes

Author： Abdul-Ghani Muhammad A   DeFronzo Ralph A  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.14, Iss.12, 2013-08, pp. : 1695-1703

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Thiazolidinediones in the treatment of Type 2 diabetes

By Greenberg Andrew S   Pittas Anastassios G  

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 5, 2002-05 ,pp. : 529-540

Informa Healthcare

Access to resources Recommend Favorite

Linagliptin for the treatment of type 2 diabetes

By Del Prato Stefano  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 17, 2011-12 ,pp. : 2759-2762

Informa Healthcare

Access to resources Recommend Favorite

Mitiglinide for type 2 diabetes treatment

By Phillippe Haley M   Wargo Kurt A  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 15, 2013-10 ,pp. : 2133-2144

Informa Healthcare

Access to resources Recommend Favorite

Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation)

By Scheen André J  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 12, 2011-12 ,pp. : 1561-1576

Informa Healthcare

Access to resources Recommend Favorite

Orlistat: In the Prevention and Treatment of Type 2 Diabetes Mellitus

By Keating G.M.   Jarvis B.  

Drugs, Vol. 61, Iss. 14, 2001-01 ,pp. : 2107-2119

Adis International

Access to resources Recommend Favorite